WO2013095316A1 - Combinaison synergique comprenant un agent anti-diabétique - Google Patents

Combinaison synergique comprenant un agent anti-diabétique Download PDF

Info

Publication number
WO2013095316A1
WO2013095316A1 PCT/TR2012/000220 TR2012000220W WO2013095316A1 WO 2013095316 A1 WO2013095316 A1 WO 2013095316A1 TR 2012000220 W TR2012000220 W TR 2012000220W WO 2013095316 A1 WO2013095316 A1 WO 2013095316A1
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
biguanide
glucosidase inhibitor
pharmaceutical composition
composition
Prior art date
Application number
PCT/TR2012/000220
Other languages
English (en)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2013095316A1 publication Critical patent/WO2013095316A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to alpha-glucosidase inhibitor and biguanide combinations, use of said combinations in the treatment of type-2 diabetes and pharmaceutical compositions comprising them.
  • alpha-glucosidase inhibitors are not directly effective on insulin secretion, they cause starch derived glucose to enter the circulation more slowly by slowing down the digestion of starchy food.
  • Some examples of the agents in this group are miglitol, acarbose and voglibose.
  • agents that act in digestive system, said agents can cause patients to experience side effects such as diarrhoea and bloating.
  • biguanides provides to lower the amount of glucose in blood circulation by enabling the cells in body to receive more glucose.
  • Agents such as metformin, phenformin, buformin can be given as examples to some of the agents in this group. Lactic acidosis, dyspepsia and diarrhoea are among the side effects frequently encountered in the patients using said drug.
  • an unexpected therapeutic benefit and especially a synergistic therapeutic benefit can be obtained in the treatment of type-2 diabetes when a combination therapy comprising alpha-glucosidase inhibitor and biguanide derivative agents are used together.
  • Said therapeutic benefit can be in form of;
  • the pharmaceutical composition in which alpha-glucosidase inhibitor and biguanide are used together or simultaneously induces a better therapeutic benefit than compositions in which said two agents are used separately.
  • using alpha-glucosidase inhibitor and biguanide combination provides the therapeutic effect to be seen in a short time and to be stronger than the effect seen when said two active agents are used separately. In this way, it is possible to provide a more effective treatment for patients.
  • the present invention relates to pharmaceutical compositions comprising an alpha-glucosidase inhibitor and a biguanide together in different dosage forms for sequential use, in different dosage forms for simultaneous use or in the same dosage form for concurrent administration.
  • the present invention provides a method that treats type-2 diabetes diseases by administrating an alpha-glucosidase inhibitor and a biguanide in effective amounts.
  • the alpha-glucosidase inhibitor that shall be used in combinations of the present invention can be selected from a group comprising miglitol, acarbose, voglibose.
  • the biguanide that shall be used in the combinations of the present invention can be selected from a group comprising metformin, phenformin, buformin.
  • the preferred combinations that can be prepared according to the invention comprise a combination of miglitol and metformin or a combination of acarbose and metformin or a combination of voglibose and metformin.
  • the present invention relates to pharmaceutical compositions comprising pharmaceutically effective amounts of an alpha-glucosidase inhibitor and a biguanide and at least one pharmaceutically acceptable excipient.
  • the alpha-glucosidase inhibitor and biguanide can be formulated with at least one pharmaceutically acceptable excipient in different formulations as well as formulated together in a single formulation.
  • the different formulations obtained can be combined in a single dosage form or can be prepared in different dosage forms. In the case that formulations are in different dosage forms, said dosage forms can be the same or different from each other.
  • the present invention relates to use of an alpha-glucosidase inhibitor and a biguanide according to the invention for preparation of a drug that shall be used in combination therapy by simultaneous, sequential or separate administration in the treatment of type-2 diabetes.
  • the alpha-glucosidase inhibitor comprised in the pharmaceutical compositions of the present invention can be in its pharmaceutically acceptable salt, hydrate, solvate, ester, enantiomer, diastereomer forms structurally and/or in amorphous, crystalline forms or a combination thereof in terms of polymorphic structure or in form of combinations thereof.
  • the biguanide comprised in the pharmaceutical compositions of the present invention can be in its pharmaceutically acceptable salt, hydrate, solvate, ester, enantiomer, diastereomer forms and/or in form of its any polymorphic form such as amorphous, crystalline form or a combination thereof.
  • metformin is used as a biguanide agent, it is preferably in salt form, more preferably in hydrochloride salt form.
  • compositions of the invention comprising an alpha-glucosidase inhibitor and a biguanide can be prepared in any one of the dosage forms such as tablet, effervescent tablet, effervescent granule, effervescent dry powder, film coated tablet, enterically coated tablet, dry powder, granule, capsule, prolonged release tablet, modified release tablet, delayed release tablet, orodispersible tablet, chewable tablet. While pharmaceutical compositions comprising an alpha-glucosidase inhibitor and a biguanide in any of these dosage forms together, they can also be in any of these dosage forms in the case that the alpha-glucosidase inhibitor and the biguanide are stored in separate dosage forms.
  • compositions comprising the combination of the invention can be in any of abovementioned dosage forms or in form of a combination of these dosage forms or in a treatment package form comprising said combination.
  • pharmaceutical formulations of the invention comprising the alpha-glucosidase inhibitor and the biguanide are preferably in form of tablet or effervescent tablet or prolonged release tablet.
  • compositions of the present invention comprising an alpha-glucosidase inhibitor and a biguanide can comprise various excipients in addition to the alpha-glucosidase inhibitor and the biguanide as active agents.
  • the pharmaceutical compositions of the present invention comprising an alpha-glucosidase inhibitor and a biguanide comprises at least one excipient selected from a group comprising disintegrant, diluent, lubricant, glidant, effervescent couple comprising at least one acidic and one basic agent, colouring agent, pH regulating agent, surfactant, stabilizing agent, sweetener and/or taste regulating agent, flavoring agent in addition to the active agents.
  • the disintegrant that can be used in the pharmaceutical compositions of the invention can be selected from a group comprising carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, microcrystalline cellulose, methyl cellulose, chitosan, starch, sodium starch glycolate.
  • the diluent that can be used in the pharmaceutical compositions of the invention can be selected from a group comprising calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrin, maltose, mannitol, simethicone, sorbitol, starch, sodium chloride, sucrose, talc, xylitol.
  • the lubricant that can be used in the pharmaceutical compositions of the invention can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, sodium benzoate, potassium benzoate, sodium lauryl sulphate, talc, stearic acid, zinc stearate.
  • the glidant that can be used in the pharmaceutical compositions of the invention can be selected from a group comprising tribasic calcium phosphate, colloidal silicone dioxide, magnesium silicate, magnesium trisilicate, talc.
  • the binder that can be used in the pharmaceutical compositions of the invention can be selected from a group comprising carboxymethyl cellulose sodium, ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminium silicate, maltodextrin, methyl cellulose, povidone, starch.
  • the acidic agent used in the effervescent couple comprising at least one acidic and one basic agent that can be used in the pharmaceutical compositions of the invention can be selected from a group comprising organic acids such as malic acid, citric acid, tartaric acid, fumaric acid; and the basic agent can be selected from a group comprising agents such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate.
  • the pH regulating agent that can be used in the pharmaceutical compositions of the invention can be selected from a group comprising citrate, phosphate, carbonate, tartrate, fumarate, acetate and amino acid salts.
  • the surfactant that can be used in the pharmaceutical compositions of the invention can be selected from a group comprising agents such as sodium lauryl sulphate, polysorbate, polyoxyethylene, polyoxypropylene glycol and the like.
  • the stabilizing agent that can be used in the pharmaceutical compositions of the invention can be selected from a group comprising tocopherol, tetrasodium edetate, nicotinamide, cyclodextrin.
  • the sweetener and/or taste regulating agent that can be used in the pharmaceutical compositions of the invention can be selected from a group comprising acesulfame, aspartame, dextrose, fructose, maltitol, maltose, mannitol, saccharine, saccharine sodium, sodium cyclamate, sorbitol, sucralose, sucrose, xylitol, sodium chloride.
  • flavouring agent that can be used in the pharmaceutical compositions of the invention can be selected from flavours comprising menthol, lemon, orange, vanilla, strawberry, raspberry, caramel and the like.
  • compositions of the invention can comprise an alpha-glucosidase inhibitor in the range of 0.1 to 99%, preferably in the range of 1 to 98%, more preferably in the range of 5 to 95 % by weight, for example, in the range of 5, 10, 15, 20, 25, 30% to 35, 40, 45, 50, 55, 60, 65, 70, 80, 90%.
  • the pharmaceutical compositions of the invention can comprise a biguanide in the range of 0.1 to 99%, preferably in the range of 1 to 98%, more preferably in the range of 5 to 95 % by weight, for example, in the range of 5, 10, 15, 20, 25, 30% to 35, 40, 45, 50, 55, 60, 65, 70, 80, 90%.
  • the pharmaceutical compositions of the invention can comprise an alpha-glucosidase inhibitor in the range of 0.01 mg to 500 mg, preferably in the range of 0.1 mg to 300 mg, more preferably in the range of 0.5 mg to 250 mg.
  • the pharmaceutical compositions of the invention can comprise a biguanide in the range of 100 mg to 1500 mg, preferably in the range of 300 mg to 1200 mg, more preferably in the range of 500 mg to 1000 mg.
  • the pharmaceutical compositions of the invention comprising an alpha-glucosidase inhibitor and a biguanide can optionally comprise a third active agent in addition to the alpha- glucosidase inhibitor and the biguanide.
  • the third active agent can be selected from a group comprising antacid, anticholinergic, antispasmodic, antiemetic, anti-diabetic, antipropulsive, antiallergic, antidiarrheal, antiobesity, antithrombotic, antifibrinolytic, antianaemic, antihypertensive, antifungal, antipruritic, antipsoriatic, antibiotic, antiseptic, antiacne, antibacterial, antimycotic, antiviral, antineoplastic, antiaritmic, antiadrenergic, antiepileptic, anti-Parkinson, antiprotozoal, antihelminthic, anti-inflammatory, diuretic, laxative, sulphonamide, imidazole, corticosteroid, tiazolidinedion, biguanide, immunostimulant, immunosuppressant, muscle relaxant, analgesic, psycholeptic, psycho analeptic peripheral vasodilator, beta block
  • a third active agent in addition to said two agents which is preferably selected form a group comprising an anti-diabetic agent meglitinide,
  • composition of the invention can be obtained by a method comprising the steps of;
  • obtained tablets can be treated with film coating agents such as sugar-based coating agents, water-soluble film coating agents, enteric coating agents, delayed release coating agents or a coating compositions comprising any combination thereof.
  • film coating agents such as sugar-based coating agents, water-soluble film coating agents, enteric coating agents, delayed release coating agents or a coating compositions comprising any combination thereof.
  • Saccharose can be used alone as sugar-based coating agent or optionally together with any of the agents such as talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatine, gum arabic, polyvinylpyrrolidone and pullulan or a combination thereof.
  • Water-soluble film coating agent can be selected from cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose; synthetic polymers such as polyvinyl acetal diethyl amino acetate, aminoalkyl methacrylate copolymer and polyvinylpyrrolidone; and polysaccharides such as pullulan or combinations thereof.
  • cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose
  • synthetic polymers such as polyvinyl acetal diethyl amino acetate, aminoalkyl methacrylate copolymer and polyvinylpyrrolidone
  • polysaccharides such as pullulan or combinations thereof.
  • Enteric coating agents can be selected from cellulose derivatives such as hydroxypropyl methyl cellulose ftalat, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate ftalat; acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S; and natural substances such as shellac or combinations thereof.
  • cellulose derivatives such as hydroxypropyl methyl cellulose ftalat, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate ftalat
  • acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S
  • natural substances such as shellac or combinations thereof.
  • Delayed release coating agents can be selected from cellulose derivatives such as ethyl cellulose; acrylic acid derivatives such as aminoalkyl methacrylate copolymer RS, ethyl acrylate-methyl methacrylate copolymer emulsion or combinations thereof.
  • the pharmaceutical composition according to the invention can be used in the prophylaxis and treatment of type-2 diabetes.
  • d 10 value of the alpha-glucosidase inhibitor of the pharmaceutical compositions of the invention is in the range of 0.1 to 50 ⁇ , preferably in the range of 1 to 30 ⁇ while dio value of the biguanide (such as metformin hydrochloride) is in the range of 0.1 to 80 ⁇ , preferably in the range of 1 to 50 ⁇ .
  • Metformin and miglitol are granulated. Obtained granules are dried and then mixed with the other excipients. Lubricant is added to the obtained mixture and the final mixture is compressed in tablet compression machine. Tablets are coated with release regulating agent and dried.
  • EXAMPLE 2 Pharmaceutical compositions comprising acarbose and metformin combination
  • Voglibose and other excipients are mixed and granulated.
  • Metformin hydrochloride and lubricant are added to the obtained granules.
  • Final composition is compressed in form of tablet and dried after coated with the coating agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des combinaisons pharmaceutiques comprenant un inhibiteur des alpha-glucosidases et une biguanide utilisée pour traiter le diabète de type 2.
PCT/TR2012/000220 2011-12-19 2012-12-19 Combinaison synergique comprenant un agent anti-diabétique WO2013095316A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2011/12588 2011-12-19
TR201112588 2011-12-19

Publications (1)

Publication Number Publication Date
WO2013095316A1 true WO2013095316A1 (fr) 2013-06-27

Family

ID=47684006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2012/000220 WO2013095316A1 (fr) 2011-12-19 2012-12-19 Combinaison synergique comprenant un agent anti-diabétique

Country Status (1)

Country Link
WO (1) WO2013095316A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528254A (ja) * 2015-09-22 2018-09-27 バイキング セラピューティクス，インコーポレーテッド グルコース産生阻害物質との併用療法
WO2018185669A1 (fr) * 2017-04-07 2018-10-11 Zenvision Pharma Llp Compositions effervescentes comprenant de la saxagliptine ou un sel de celle-ci
WO2019078663A3 (fr) * 2017-10-20 2019-06-06 주식회사 노브메타파마 Composition pharmaceutique pour prévenir et traiter le diabète contenant un sel de zinc, un cyclo-hispro et un antidiabétique à titre de principes actifs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1964562A1 (fr) * 2005-12-20 2008-09-03 Espinosa Abdala, Leopoldo de Jesús Compositions pharmaceutiques comprenant des substances derivees de la thiazolidinedione combinees au biguanide utilisees contre le diabete sucre de type 2
WO2010138535A1 (fr) * 2009-05-27 2010-12-02 Bristol-Myers Squibb Company Méthodes pour le traitement de diabète de type 2 chez des patients résistant à un traitement précédent avec d'autres médicaments anti-diabétiques employant un inhibiteur sglt2 et compositions associées

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1964562A1 (fr) * 2005-12-20 2008-09-03 Espinosa Abdala, Leopoldo de Jesús Compositions pharmaceutiques comprenant des substances derivees de la thiazolidinedione combinees au biguanide utilisees contre le diabete sucre de type 2
WO2010138535A1 (fr) * 2009-05-27 2010-12-02 Bristol-Myers Squibb Company Méthodes pour le traitement de diabète de type 2 chez des patients résistant à un traitement précédent avec d'autres médicaments anti-diabétiques employant un inhibiteur sglt2 et compositions associées

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAVELES E B: "Trends in diabetes care", DRUG TOPICS, ADVANSTAR MEDICAL ECONOMICS HEALTHCARE COMMUNICATIONS, US, vol. 145, no. 19 Suppl, 1 October 2001 (2001-10-01), pages 29s - 36s, XP009168764, ISSN: 0012-6616 *
WARREN R E: "The stepwise approach to the management of type 2 diabetes", DIABETES RESEARCH AND CLINICAL PRACTICE 200409 IE, vol. 65, no. SUPPL., September 2004 (2004-09-01), pages S3 - S8, XP027173735, ISSN: 0168-8227 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528254A (ja) * 2015-09-22 2018-09-27 バイキング セラピューティクス，インコーポレーテッド グルコース産生阻害物質との併用療法
EP3352762A4 (fr) * 2015-09-22 2019-06-05 Viking Therapeutics, Inc. Thérapies combinées à des inhibiteurs de production de glucose
WO2018185669A1 (fr) * 2017-04-07 2018-10-11 Zenvision Pharma Llp Compositions effervescentes comprenant de la saxagliptine ou un sel de celle-ci
WO2019078663A3 (fr) * 2017-10-20 2019-06-06 주식회사 노브메타파마 Composition pharmaceutique pour prévenir et traiter le diabète contenant un sel de zinc, un cyclo-hispro et un antidiabétique à titre de principes actifs
US11607441B2 (en) 2017-10-20 2023-03-21 Novmetapharma Co., Ltd. Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients

Similar Documents

Publication Publication Date Title
ES2272082T3 (es) Formulaciones farmaceuticas de liberacion controlada que contienen un inhibidor de pde-5 de gmpc.
US20070160664A1 (en) Pharmaceutical compositions comprising of proton pump inhibitor and prokinetic agent
EP3731837A2 (fr) Combinaison contenant de la linagliptine et de la metformine
WO2013115742A1 (fr) Composition pharmaceutique contenant un inhibiteur de l'alpha-glucosidase
EP3976014A1 (fr) Combinaison comprenant de l'alogliptine et de la metformine
WO2013095316A1 (fr) Combinaison synergique comprenant un agent anti-diabétique
WO2013115744A1 (fr) Procédé de préparation de compositions pharmaceutiques (effervescentes) contenant un inhibiteur de l'apha-glucosidase (p. ex. voglibose et metformine)
WO2013115740A1 (fr) Combinaison synergique contenant un dérivé de méglitinide et de l'acide lipoïque
WO2013077824A1 (fr) Procédé de fabrication d'une préparation comprenant de la metformine
WO2013109227A1 (fr) Compositions pharmaceutiques contenant du ceftibutène
WO2013115738A1 (fr) Acarbose micronisée
CA2855503A1 (fr) Formulation a liberation immediate de 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide
WO2013077819A1 (fr) Préparations pharmaceutiques comprenant du natéglinide
WO2018185669A1 (fr) Compositions effervescentes comprenant de la saxagliptine ou un sel de celle-ci
WO2013077825A1 (fr) Procédé de fabrication d'une préparation comprenant de la metformine
WO2014104989A1 (fr) Compositions pharmaceutiques comprenant de l'aripiprazole
WO2013077822A1 (fr) Nouvelles préparations pour le traitement du diabète
WO2013074049A1 (fr) Metformine micronisée
ES2435966T3 (es) Combinaciones de vildagliptina y glimepirida
WO2013077823A1 (fr) Préparations à dispersion rapide contenant du natéglinide
WO2013100879A1 (fr) Compositions pharmaceutiques contenant de la quétiapine
WO2019132833A1 (fr) Combinaison à libération modifiée comprenant de la linagliptine et de la metformine
WO2013115741A1 (fr) Compositions pharmaceutiques contenant un inhibiteur de l'alpha-glucosidase
WO2019087054A1 (fr) Nouvelle composition pharmaceutique comprenant un inhibiteur de dpp-4, de l'acide alpha-lipoïque et de la vitamine b12
WO2019212427A2 (fr) Compositions comprenant de l'erdostéine et de l'acide ascorbique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12823175

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12823175

Country of ref document: EP

Kind code of ref document: A1